SCHEMBL6352409

SCHEMBL6352409

Clc1cc(Nc2ccc(Cl)c(Cl)c2)nc(N2CCN(c3ccccn3)CC2)n1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLA1 P09884 1/20 0.47
NPC1 O15118 1/20 0.44
HK1 P19367 1/20 0.44
RAB9A P51151 1/20 0.44
HKDC1 Q2TB90 1/20 0.44
MAPT P10636 3/20 0.43
POLB P06746 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
KDM4E B2RXH2 3/20 0.43
HSD17B10 Q99714 2/20 0.43
LMNA P02545 2/20 0.43
HPGD P15428 2/20 0.43
TP53 P04637 1/20 0.43
TSHR P16473 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
MALT1 Q9UDY8 1/20 0.41
ALDH1A1 P00352 4/20 0.41
GAA P10253 1/20 0.41
USP2 O75604 1/20 0.41
MAPK1 P28482 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6354646 0.92 GALR1 (0.47) NPC1HK1RAB9AHKDC1MAPT
SCHEMBL3247965 0.86 MAPT (0.42) NPC1HK1RAB9AHKDC1MAPT
SCHEMBL8092857 0.79 MAPT (0.51) NPC1RAB9AMAPTPOLBNPSR1
SCHEMBL3240653 0.75 ALDH1A1 (0.48) MAPTPOLBNPSR1KDM4EHSD17B10
SCHEMBL3247480 0.74 LMNA (0.51) MAPTNPSR1KDM4EHSD17B10LMNA
SCHEMBL3240505 0.74 MAPT (0.39) MAPTPOLBNPSR1KDM4EHSD17B10
SCHEMBL3241392 0.72 GALR2 (0.59) MAPTPOLBKDM4EHSD17B10LMNA
SCHEMBL3247614 0.72 MAPT (0.45) NPC1HK1RAB9AHKDC1MAPT
SCHEMBL8254119 0.72 KDM4E (0.48) RAB9AMAPTPOLBNPSR1KDM4E
SCHEMBL3247212 0.72 GALR1 (0.47) NPC1HK1RAB9AHKDC1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6936607-B2 2,4,6-Triaminopyrimidines for the treatment of depression and/or anxiety H. LUNOBECK A/S (DK) 2005-08-30 US disclosed
US-20040082587-A1 2,4,6-Triaminopyrimidines for the treatment of depression and/or anxiety H. LUNDBECK A/S (DK) 2004-04-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040082587-A1 2,4,6-Triaminopyrimidines for the treatment of depression and/or anxiety GALR3, GALR2, GALR1 POLA1 2699/4885NPC1 4045/4885HK1 982/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.